Rapid CAR-T manufacturing with low-intensity priming enhances CAR-T cell fitness and limits inflammatory programming in a phase 1 study.

PrimeCAR, a 2-day manufacturing strategy with low-intensity priming, enhances CAR-T cell fitness and limits inflammatory programming in a phase 1 study.

• Why it matters: Prolonged ex vivo activation in conventional CAR-T manufacturing may impair T cell fitness and promote inflammatory differentiation, reducing therapeutic efficacy.
• What they did: Researchers developed PrimeCAR by combining low-intensity anti-CD3 priming with IL-7 and IL-21, producing cells with preserved stemness and a primed naive T cell-like state, and tested them in xenograft models and phase 1 clinical trials involving relapsed or refractory B cell cancers.
• The result: PrimeCAR cells showed improved expansion, persistence, and durable antitumor activity, with encouraging clinical responses and a favorable safety profile, suggesting a practical approach to enhance CAR-T therapy.